Neurofibromin pathway modulators
The present invention encompasses methods for treating neurofibromatosis.
1. A method for treating neurofibromatosis, the method comprising administering to a subject in need thereof an inhibitor of nucleophosmin (NPM), wherein the inhibitor is NSC3848884 (2-(dimethylsulfamoylamino)-N-[(4-fluorophenyl)methylideneamino]acetamide).
2. The method of claim 1 , further comprising administering an inhibitor of Rac1.
3. The method of claim 1 , further comprising administering rapamycin.
4. A method for treating neurofibromatosis, the method comprising administering to a subject in need thereof an inhibitor of Rac1, wherein the inhibitor is NSC553502 (trimethylsilyl 2-methyl-2,3-bis(trimethylsilyloxy)propanoate) or EHT1864 (5-(5-(7-(Trifluoromethyl)quinolin-4-ylthio)pentyloxy)-2-(morpholinomethyl)-4H-pyran-4-one dihydrochloride).
5. The method of claim 4 , further comprising administering an inhibitor of nucleophosmin (NPM).
6. The method of claim 4 , further comprising administering rapamycin.